Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05443126 Phase 1, Phase 2
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancie...
Condition
NSCLC
Enrollment
265 pts
Location
United States, France, Germany
Sponsor
Ellipses Pharma
NCT03947385 Phase 1, Phase 2
Recruiting
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRK...
Condition
Metastatic Uveal Melanoma
Enrollment
336 pts
Location
United States, Australia, Canada
Sponsor
IDEAYA Biosciences
NCT06877650 Phase 1, Phase 2
Recruiting
First-in-Human Investigation of JMT108 Injection in Participants With Advanced M...
Condition
Advanced Malignant Tumors
Enrollment
436 pts
Location
China
Sponsor
Shanghai JMT-Bio Inc.
NCT05038150 Phase 1, Phase 2
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
Condition
Advanced Solid Tumor
Enrollment
70 pts
Location
United States, China
Sponsor
Guangzhou Sinogen Pharmaceutic
NCT07105215 Phase 1, Phase 2
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the ...
Condition
Solid Tumors
Enrollment
312 pts
Location
China
Sponsor
RemeGen Co., Ltd.
NCT06708663 Phase 1, Phase 2
Recruiting
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Condition
Biliary Tract Cancer
Enrollment
124 pts
Location
China
Sponsor
Hangzhou Hanx Biopharmaceutica
NCT03384238 Phase 1, Phase 2
Recruiting
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Condition
Pancreatic Adenocarcinoma
Enrollment
27 pts
Location
United States
Sponsor
George Poultsides
NCT07391215 Phase 1, Phase 2
Recruiting
5G-PEARL: Paxalisib in Malignant Brain Tumours
Condition
Malignant Primary Gliomas
Enrollment
64 pts
Location
United Kingdom
Sponsor
Institute of Cancer Research,
NCT03471260 Phase 1, Phase 2
Recruiting
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With ...
Condition
Acute Myeloid Leukemia
Enrollment
96 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06896890 Phase 1, Phase 2
Recruiting
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with...
Condition
NSCLC (advanced Non-small Cell Lung Cancer)
Enrollment
32 pts
Location
Belgium, France, Spain
Sponsor
Inhatarget Therapeutics
NCT07556276 Phase 1, Phase 2
Recruiting
Study of CMTS1215 Injection in Patients With Solid Tumors
Condition
Solid Tumor
Enrollment
20 pts
Location
China
Sponsor
The Second Hospital of Nanjing
NCT07392255 Phase 1, Phase 2
Recruiting
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx00...
Condition
Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment
75 pts
Location
United States, United Kingdom
Sponsor
Complement Therapeutics
NCT03024008 Phase 1, Phase 2
Recruiting
Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Au...
Condition
Bone Fracture
Enrollment
40 pts
Location
Israel
Sponsor
BonusBio Group Ltd
NCT07046806 Phase 1, Phase 2
Recruiting
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema...
Condition
Hereditary Angioedema (HAE)
Enrollment
10 pts
Location
United States
Sponsor
Institute for Asthma and Aller
NCT02174549 Phase 1, Phase 2
Recruiting
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Condition
Hepatocellular Carcinoma
Enrollment
25 pts
Location
United States
Sponsor
Teclison Ltd.
NCT06868849 Phase 1, Phase 2
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
Condition
Non Small Cell Lung Cancer
Enrollment
307 pts
Location
China
Sponsor
Shanghai JMT-Bio Inc.
NCT03676504 Phase 1, Phase 2
Recruiting
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T ...
Condition
Acute Lymphoblastic Leukemia, Adult
Enrollment
68 pts
Location
Germany
Sponsor
University Hospital Heidelberg
NCT06481735 Phase 1, Phase 2
Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T C...
Condition
Acute Lymphocytic Leukemia
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT06853015 Phase 1, Phase 2
Recruiting
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Condition
SCI - Spinal Cord Injury
Enrollment
27 pts
Location
United States
Sponsor
Shirley Ryan AbilityLab
NCT07368608 Phase 1, Phase 2
Recruiting
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated ...
Condition
Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
Enrollment
340 pts
Location
China
Sponsor
BeBetter Med Inc
NCT07252050 Phase 1, Phase 2
Recruiting
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Di...
Condition
Sickle Cell Disease
Enrollment
24 pts
Location
United States
Sponsor
Arkansas Children's Hospital R
NCT05685368 Phase 1, Phase 2
Recruiting
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle C...
Condition
Race-related Stress
Enrollment
66 pts
Location
United States
Sponsor
Children's Hospital Los Angele
NCT05953350 Phase 1, Phase 2
Recruiting
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effe...
Condition
Inhibition of Autophagy Synergizes Anti-tumor Effect
Enrollment
29 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT04106115 Phase 1, Phase 2
Recruiting
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive ...
Condition
Bladder Cancer
Enrollment
52 pts
Location
United Kingdom
Sponsor
University College, London
NCT05475925 Phase 1, Phase 2
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotox...
Condition
LGLL - Large Granular Lymphocytic Leukemia
Enrollment
200 pts
Location
United States, Australia, France
Sponsor
Dren Bio
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology